.gif)
Oncotelic Therapeutics, Inc.
30
Recent public coverage of Oncotelic Therapeutics, Inc. focuses on insider trading and hedge fund activity ahead of earnings announcements.
- An earnings preview published on April 8, 2025, highlights recent insider trading and hedge fund activity related to Oncotelic Therapeutics, Inc.[N1]
Oncotelic Therapeutics, Inc. is a publicly traded company with limited publicly available information regarding its sector, industry, or detailed business operations. Financial disclosures indicate minimal revenue and significant net income in recent fiscal years, alongside constrained liquidity. The company’s recent news coverage primarily addresses market-related activities such as insider trading and hedge fund involvement.
Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Oncotelic Therapeutics, Inc. reported limited revenue of $70,000 for fiscal year 2024 and a net income of approximately $249 million for fiscal year 2025. The company exhibits low liquidity with a current ratio of 0.07 and a cash ratio of 0.15 as of December 31, 2025. Recent news coverage centers on insider trading and hedge fund activity rather than operational developments.
The company reported a substantial net income figure for fiscal year 2025 despite low revenue, which may reflect non-operational gains or other financial factors. Insider trading and hedge fund activity reported in recent news could indicate investor interest or strategic positioning.
Oncotelic Therapeutics, Inc. shows very low liquidity ratios, with current liabilities significantly exceeding current assets, which may pose financial risk. The minimal revenue and lack of detailed operational disclosures reduce transparency and increase uncertainty about the company’s core business viability.
There is insufficient publicly disclosed information to assess Oncotelic Therapeutics, Inc.'s competitive advantages or moat. The lack of detailed business model and operational data limits visibility into its market positioning or proprietary strengths.
• Liquidity Risk: The company’s current ratio of 0.07 and cash ratio of 0.15 as of December 31, 2025, indicate limited short-term financial flexibility to meet obligations.
• Information Transparency: Limited disclosure on business operations, sector, and industry reduces visibility into the company’s strategic direction and operational health.
• Market Activity Focus: Recent news coverage centers on insider trading and hedge fund activity rather than operational progress, which may reflect market speculation rather than fundamental business developments.
Business trends: Limited revenue generation with significant net income reported; market interest reflected in insider and hedge fund activity.
Execution milestones: No disclosed operational milestones; financial reporting continues with SEC filings.
Key risks: Low liquidity and limited transparency on business operations increase uncertainty about financial and strategic stability.
Low visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Oncotelic Therapeutics, Inc. is a publicly traded company with ticker OTLC.
- As of September 30, 2025, the company held $409,000 in cash and cash equivalents.
- The company had short-term investments of $2,303,000 as of March 31, 2017.
- As of December 31, 2025, current assets were $1,198,252 and current liabilities were $18,143,278, resulting in a current ratio of 0.07 and a cash ratio of 0.15, indicating low liquidity.
- The company reported revenue of $70,000 for the fiscal year ending December 31, 2024.
- Net income for the fiscal year ending December 31, 2025, was $249,279,832.
- Basic and diluted earnings per share for the fiscal year ending December 31, 2025, were both $0.59 per share.
- Financial figures are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
- Recent news coverage includes an earnings preview focusing on insider trading and hedge fund activity as of April 8, 2025.
Generated 2026-04-18
- S1 | 2026-04-15 | 10-K
- N1 | 2025-04-08 | www.nasdaq.com | $OTLC Earnings Preview: Recent $OTLC Insider Trading, Hedge Fund Activity, and More | https://www.nasdaq.com/articles/otlc-earnings-preview-recent-otlc-insider-trading-hedge-fund-activity-and-more
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.
Generated by Valye SEC Pipeline Engine